RHB-106 is a proprietary investigational encapsulated oral bowel preparation licensed to Salix Pharmaceuticals.

RHB-106 was acquired from Sydney-based Giaconda [ASX: GIA] in August 2010.

In February 2014 RedHill Biopharma and Salix Pharmaceuticals (acquired in 2015 by Valeant Pharmaceuticals) announced that they have entered into an exclusive agreement by which Salix has licensed the worldwide exclusive rights to RedHill’s RHB-106 encapsulated formulation for bowel preparation and rights to other purgative developments.

RHB-106 is an encapsulated formulation intended for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures, including diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The RHB-106 preparation is a tasteless solid oral dosage potentially allowing an unobstructed procedure with reduced side-effects and improved compliance. It avoids patient exposure to the often unacceptable taste of current products.

A Phase 2a study with RHB-106 was concluded in Australia in 2005 with 62 patients. The results demonstrated significantly improved patient response and equal bowel cleansing.